Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Adapted resiliency program for parents of adolescents and young adults with cancer

Official title: The RAISE Study: Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer

Run by Massachusetts General Hospital · NCT07139769 · Data updated 2026-11-12

This project will try a group-based resiliency program to reduce distress in parents who care for adolescents and young adults (ages 15–39) with cancer.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment48 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedOctober 22, 2025
Main results expectedMarch 2027
Study endsMay 2027
Registry record updatedNovember 10, 2026
Trial IDNCT07139769 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking parents or guardians aged over 18 who are the primary informal caregiver of a child aged 15–39 currently receiving cancer treatment and who report at least mild distress (NCCN Distress Thermometer ≥2).

Probably not a fit

This intervention is unlikely to help parents with active psychosis or current suicidal ideation, non-English speakers, or caregivers who cannot participate at the study location or who have another household member already enrolled in the same study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The team will adapt an evidence-supported, group-based Stress Management and Resiliency Training program (SMART-3RP) specifically for parents of AYA with cancer and iteratively refine it using feedback collected through interviews and surveys. After adaptation, the refined intervention will be piloted to measure feasibility, acceptability, and early signs that it can lower parental psychological distress. The pilot will enroll English-speaking parents or guardians over age 18 who are primary informal caregivers for an AYA currently in cancer treatment and who report at least mild distress. Outcomes will include measures of feasibility (enrollment and retention), participant satisfaction, and changes in distress levels.

Why it matters

Potential benefit: If successful, the intervention could reduce stress and improve coping for parents, which may enhance caregiver well-being and family functioning.

How similar studies have gone: SMART-3RP and related resiliency programs have shown benefits for stress reduction in other medical and caregiving populations, but adapting this program specifically for parents of AYA with cancer is a novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Self-identifying parent/guardian who provides a primary informal caregiving role in their child's cancer
* Recipient of caregiving is aged between 15 and 39 years and is receiving treatment for cancer at the Mass General Brigham Cancer
* Participant must score equal to or greater than 2 (out of a possible 10) on the National Comprehensive Cancer Network Distress Thermometer
* English-speaking
* Aged over 18 years

Exclusion Criteria:

-Active symptoms of psychosis or suicidal ideation that would preclude safe participation

Where it's running

  • Mass General Brigham Cancer Institute at Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.